Inflammatory Diseases Recruiting Phase 2 Trials for Secukinumab (DB09029)

Also known as: Inflammatory Disease

IndicationStatusPhase
DBCOND0041144 (Inflammatory Diseases)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03651518Personalized Therapies in Inflammatory Complex DiseaseTreatment